The present review outlines current management issues and controversies related to Helicobacter pylori infection.
Clearance of this infection markedly reduces the likelihood of duodenal and gastric ulcer recurrence and may result in the regression of low grade primary gastric lymphoma.
Recent therapeutic advances have seen the development of simpler drug regimens to treat H. pylori that have fewer side effects and are shorter in duration.
Clearance of the infection can be achieved in 80-95% of patients treated, depending on the drug regimen used, compliance with medications and antibiotic sensitivity.
In developed nations reinfection is uncommon after successful treatment.
Data do not currently support treatment of this infection for non-ulcer dyspepsia or for the prevention of gastric cancer, although whether certain individuals or populations may benefit from such treatment remains to be clarified.
Mots-clés Pascal : Gastrite, Campylobactériose, Bactériose, Infection, Helicobacter pylori, Spirillaceae, Spirillales, Bactérie, Association morbide, Carcinome, Estomac, Ulcère, Gastroduodénal, Diagnostic, Dépistage, Traitement, Article synthèse, Homme, Appareil digestif pathologie, Estomac pathologie, Tumeur maligne, Intestin pathologie
Mots-clés Pascal anglais : Gastritis, Campylobacter infection, Bacteriosis, Infection, Helicobacter pylori, Spirillaceae, Spirillales, Bacteria, Concomitant disease, Carcinoma, Stomach, Ulcer, Gastroduodenal, Diagnosis, Medical screening, Treatment, Review, Human, Digestive diseases, Gastric disease, Malignant tumor, Intestinal disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0311134
Code Inist : 002B05B02F. Création : 15/07/1997.